• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Radium-223 plus abiraterone in metastatic castration-resistant prostate cancer: a cautionary tale.镭-223联合阿比特龙治疗转移性去势抵抗性前列腺癌：一则警示故事。
Transl Androl Urol. 2019 Jul;8(Suppl 3):S341-S345. doi: 10.21037/tau.2019.05.02.
2
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.镭-223 联合醋酸阿比特龙和泼尼松或泼尼松龙治疗去势抵抗性前列腺癌和骨转移患者（ERA 223）：一项随机、双盲、安慰剂对照、III 期临床试验。
Lancet Oncol. 2019 Mar;20(3):408-419. doi: 10.1016/S1470-2045(18)30860-X. Epub 2019 Feb 6.
3
A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.镭-223 联合阿比特龙或恩扎鲁胺治疗转移性去势抵抗性前列腺癌的真实世界评估。
PLoS One. 2021 Jun 21;16(6):e0253021. doi: 10.1371/journal.pone.0253021. eCollection 2021.
4
Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group.镭-223 在转移性去势抵抗性前列腺癌的不断发展的治疗选择中的应用：来自欧洲专家工作组的建议。
Eur Urol Oncol. 2020 Aug;3(4):455-463. doi: 10.1016/j.euo.2019.02.007. Epub 2019 Mar 26.
5
Enzalutamide Prior to Radium-223 Is Associated with Better Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Compared to Abiraterone-A Retrospective Study.与阿比特龙A相比，镭-223治疗前使用恩杂鲁胺可使转移性去势抵抗性前列腺癌患者的总生存期更长——一项回顾性研究。
Cancers (Basel). 2023 Jul 6;15(13):3516. doi: 10.3390/cancers15133516.
6
Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer.化疗、恩扎鲁胺、阿比特龙和镭 223 与转移性去势抵抗性前列腺癌老年男性认知功能的关联。
JAMA Netw Open. 2021 Jul 1;4(7):e2114694. doi: 10.1001/jamanetworkopen.2021.14694.
7
Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer.荷兰转移性去势抵抗性前列腺癌镭-223 的经济价值。
Appl Health Econ Health Policy. 2018 Feb;16(1):133-143. doi: 10.1007/s40258-017-0350-x.
8
A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide.镭-223 单独或联合醋酸阿比特龙/泼尼松或恩扎鲁胺治疗转移性去势抵抗性前列腺癌（mCRPC）患者的定量骨扫描反应的随机 IIa 期研究。
ESMO Open. 2021 Apr;6(2):100082. doi: 10.1016/j.esmoop.2021.100082. Epub 2021 Mar 19.
9
A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 study.镭-223 与安慰剂联合醋酸阿比特龙和泼尼松治疗去势抵抗性转移性前列腺癌的随机、双盲、对照研究：ERA 223 研究中日本患者的亚组分析。
Int J Clin Oncol. 2020 Apr;25(4):720-731. doi: 10.1007/s10147-019-01589-6. Epub 2019 Dec 10.
10
Treatment of Metastatic, Castration-resistant, Docetaxel-resistant Prostate Cancer: A Systematic Review of Literature With a Network Meta-analysis of Randomized Clinical Trials.转移性、去势抵抗性、多西他赛耐药性前列腺癌的治疗：一项基于随机临床试验网络荟萃分析的文献系统评价
Rev Recent Clin Trials. 2018;13(3):226-237. doi: 10.2174/1574887113666180404120540.

引用本文的文献

1
Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label study.镭-223联合恩杂鲁胺治疗转移性去势抵抗性前列腺癌：一项多中心、II期开放标签研究。
Ther Adv Med Oncol. 2021 Sep 6;13:17588359211042691. doi: 10.1177/17588359211042691. eCollection 2021.
2
Recent Advances in Nanomedicine for the Diagnosis and Treatment of Prostate Cancer Bone Metastasis.纳米医学在前列腺癌骨转移诊断和治疗中的新进展。
Molecules. 2021 Jan 13;26(2):384. doi: 10.3390/molecules26020384.
3
Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center.镭-223 治疗转移性去势抵抗性前列腺癌：美国一家三级肿瘤中心的回顾性研究。
Prostate Cancer Prostatic Dis. 2021 Mar;24(1):210-219. doi: 10.1038/s41391-020-00271-7. Epub 2020 Aug 19.
4
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.镭-223 与恩扎卢胺或阿比特龙/泼尼松同期或序贯治疗：转移性去势抵抗性前列腺癌患者的真实世界临床结局。
Prostate Cancer Prostatic Dis. 2020 Dec;23(4):680-688. doi: 10.1038/s41391-020-0236-0. Epub 2020 May 13.

本文引用的文献

1
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.镭-223 联合醋酸阿比特龙和泼尼松或泼尼松龙治疗去势抵抗性前列腺癌和骨转移患者（ERA 223）：一项随机、双盲、安慰剂对照、III 期临床试验。
Lancet Oncol. 2019 Mar;20(3):408-419. doi: 10.1016/S1470-2045(18)30860-X. Epub 2019 Feb 6.
2
The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer.鉴于新的前列腺癌治疗方法的出现，双膦酸盐或地舒单抗的作用。
Cancer Treat Rev. 2018 Jul;68:25-37. doi: 10.1016/j.ctrv.2018.04.014. Epub 2018 May 3.
3
Metastatic Prostate Cancer.转移性前列腺癌
N Engl J Med. 2018 Feb 15;378(7):645-657. doi: 10.1056/NEJMra1701695. Epub 2018 Feb 7.
4
eRADicAte: A Prospective Evaluation Combining Radium-223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration-Resistant Prostate Cancer.eRADicAte：镭-223 二氯化物联合醋酸阿比特龙加泼尼松治疗去势抵抗性前列腺癌的前瞻性评估。
Clin Genitourin Cancer. 2018 Apr;16(2):149-154. doi: 10.1016/j.clgc.2017.10.022. Epub 2017 Nov 7.
5
Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study.阿比特龙与恩杂鲁胺序贯治疗转移性去势抵抗性前列腺癌男性患者的回顾性研究
Prostate. 2017 Jan;77(1):33-40. doi: 10.1002/pros.23246. Epub 2016 Aug 16.
6
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.镭-223 联合治疗转移性去势抵抗性前列腺癌患者：一项国际性、早期准入、开放标签、单臂 3b 期试验。
Lancet Oncol. 2016 Sep;17(9):1306-16. doi: 10.1016/S1470-2045(16)30173-5. Epub 2016 Jul 26.
7
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.AR-V7 与前列腺癌中对恩杂鲁胺和阿比特龙的耐药性。
N Engl J Med. 2014 Sep 11;371(11):1028-38. doi: 10.1056/NEJMoa1315815. Epub 2014 Sep 3.
8
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.EAU 前列腺癌指南。第二部分：晚期、复发性和去势抵抗性前列腺癌的治疗。
Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.
9
Alpha emitter radium-223 and survival in metastatic prostate cancer.α 粒子发射体镭-223 与转移性前列腺癌的生存。
N Engl J Med. 2013 Jul 18;369(3):213-23. doi: 10.1056/NEJMoa1213755.
10
Post-docetaxel options for further survival benefit in metastatic castration-resistant prostate cancer: Questions of choice.多西他赛后用于转移性去势抵抗性前列腺癌进一步生存获益的治疗选择：选择的问题
Can Urol Assoc J. 2013 Jan-Feb;7(1-2 Suppl 1):S11-7. doi: 10.5489/cuaj.274.

Radium-223 plus abiraterone in metastatic castration-resistant prostate cancer: a cautionary tale.

作者信息

Sedhom Ramy, Antonarakis Emmanuel S

机构信息

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.

出版信息

Transl Androl Urol. 2019 Jul;8(Suppl 3):S341-S345. doi: 10.21037/tau.2019.05.02.

DOI:10.21037/tau.2019.05.02
PMID:31392164
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6642951/
Abstract
摘要